

FOR IMMEDIATE RELEASE

February 22, 2024

Contacts:

Marijn Hendrickx

Managing Director

mh@terraproteinequity.com

+31 6 5711 5852

<https://www.terraproteinequity.com>

Thomas Tillett

CEO, MBF Therapeutics

ttillett@mbftherapeutics.com

www.mbftherapeutics.com

Press Release

Pennsylvania, United States – In a strategic move to accelerate growth, TerraProtein Equity Partners and MBF Therapeutics Inc. have entered into an Engagement Agreement, leveraging TerraProtein's advisory expertise to secure growth capital for MBF Therapeutics' innovative animal health initiatives.

TerraProtein Equity Partners, renowned for their advisory services in agtech venture capital and private equity, together with MBF Therapeutics Inc., a leader in the field of DNA-based immunotherapeutic vaccines for animals, are excited to announce this partnership. The agreement enlists TerraProtein Equity Partners as consultants to support the fundraising efforts for MBFT's animal health sector, with additional backing from ACP Capital Markets.

"After an exceptionally productive few months, marked by the launch of key partnerships and breakthrough clinical data for our T-Max Precision™ DNA vaccine technology, in particular with our porcine and poultry vaccines, we are eager to secure significant new investment to rapidly advance these programs. This funding is vital for the commercial rollout of our novel vaccine offerings for swine and poultry," explained Thomas Tillett, CEO of MBF Therapeutics. "Our choice of TerraProtein as a partner in this venture stems from their unmatched expertise and connections within the industry. Our board and I have long been aware of the strategic value TerraProtein brings to the table."

About TerraProtein Equity Partners

TerraProtein Equity Partners B.V. is a specialized strategic advisory firm that focuses on the agricultural sector. The firm's partners are seasoned operators and our clients benefit

from access to investor and operator relationships that were built by them over decades and through our successfully completed transactions. Our network is global and reaches from large established multi-national (investment) groups to earlier stage businesses and private investor networks. We provide ideas, build business cases and provide strategic advisory services ultimately to progress the agricultural industry to become more efficient and sustainable and we are thrilled about the many growth opportunities that are available to the sector. Should you wish to know more? Then please contact mh@terraproteinequity.com for your strategic advisory inquiries.

About MBF Therapeutics

US-based MBF Therapeutics has developed and patented an innovative, proprietary T-Max Precision™ DNA vaccine platform to deliver vaccines mucosally that provide safe, durable, broad cross-protection against diseases of concern to livestock and poultry. T-Max vaccines elicit precise and robust T cell-mediated effector and memory immune responses in mucosal tissues that rapidly clear viruses to limit disease to the site of infection, block spread in the body, and prevent transmission from the infected animal to other in-contact animals. MBFT's lead vaccines are focused on Porcine Reproductive & Respiratory Syndrome, African Swine Fever, and Infectious laryngotracheitis virus in chickens. For more information about MBF Therapeutics, visit www.mbftherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities of the issuer. Any offer to sell or solicitation of an offer to buy securities of the issuer may only be made pursuant to a valid prospectus pursuant to an effective registration statement or pursuant to a valid exemption from registration under the Securities Act of 1933, as amended and the rules and regulations promulgated thereunder.

###

Copyright © 2024 **MBF Therapeutics**

Next Generation Immunotherapeutics for Animal Health

All rights reserved.